{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:10Z","timestamp":1787071270476,"version":"build-2736575974"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Uveitis is an inflammatory condition involving the iris, ciliary body, and choroid, and it represents a significant cause of vision loss in both children and adults. The primary goals of uveitis management are to control inflammation, prevent recurrences, and minimize structural damage and subsequent visual impairment. Currently, corticosteroids remain the mainstay of therapy for noninfectious uveitis. In patients with sight-threatening disease, immunosuppressive or steroid-sparing agents are commonly employed. However, for individuals who are intolerant of or refractory to corticosteroids and conventional immunosuppressive therapies, biologic agents have emerged as effective alternative treatments. Among these, anti-tumor necrosis factor alpha (TNF-\u03b1) agents have demonstrated efficacy in both uveitis and systemic autoimmune disorders. Adalimumab, an anti-TNF-\u03b1 agent, was the first biologic approved by the U.S. Food and Drug Administration for the treatment of noninfectious uveitis. Prior to initiating biologic therapy, potential safety concerns, including the risk of infections and demyelinating diseases, must be carefully evaluated. Other biologic agents, such as interferons, interleukin inhibitors, and Janus kinase inhibitors, are emerging as promising therapeutic options for noninfectious uveitis. Further studies are required to better establish the long-term safety and efficacy of biologic therapies. This review highlights the role and effectiveness of biologic agents in the management of noninfectious uveitis.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3239_25","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:02:05Z","timestamp":1773331325000},"page":"837-844","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Noninfectious uveitis: Management with biologic agents"],"prefix":"10.4103","volume":"74","author":[{"given":"SR","family":"Rathinam","sequence":"first","affiliation":[{"name":"Uveitis Service, Aravind Eye Hospital and PG Institute of Ophthalmology, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somanath","family":"Anjana","sequence":"additional","affiliation":[{"name":"Uveitis Service, Aravind Eye Hospital and PG Institute of Ophthalmology, Madurai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"R1-20260527","doi-asserted-by":"crossref","first-page":"1412930","DOI":"10.3389\/fopht.2024.1412930","article-title":"Update on non-infectious uveitis treatment: Anti-TNF-alpha and beyond","volume":"4","author":"Chauhan","year":"2024","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"R2-20260527","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09273948.2016.1196713","article-title":"A focus on the epidemiology of uveitis","volume":"26","author":"Tsirouki","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R3-20260527","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/antib13040086","article-title":"Ophthalmic use of targeted biologics in the management of intraocular diseases: Current and emerging therapies","volume":"13","author":"Zong","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"R4-20260527","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fphar.2020.00655","article-title":"New pharmacological strategies for the treatment of non-infectious uveitis: A minireview","volume":"11","author":"Valenzuela","year":"2020","journal-title":"Front Pharmacol"},{"key":"R5-20260527","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"R6-20260527","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40135-016-0090-3","article-title":"Uveitic macular edema: Treatment update","volume":"4","author":"Goldhardt","year":"2016","journal-title":"Curr Ophthalmol Rep"},{"key":"R7-20260527","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40259-018-0307-0","article-title":"SB5: An adalimumab biosimilar","volume":"32","author":"Frampton","year":"2018","journal-title":"BioDrugs"},{"key":"R8-20260527","first-page":"1043","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis","volume":"35","author":"Leinonen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R9-20260527","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","article-title":"Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies","volume":"123","author":"Cordero-Coma","year":"2016","journal-title":"Ophthalmology"},{"key":"R10-20260527","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","article-title":"Long-term golimumab for severe uveitis","volume":"22","author":"Miserocchi","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"R11-20260527","first-page":"680","article-title":"Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis","volume":"37","author":"Tosi","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R12-20260527","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R13-20260527","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20260527","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by corticosteroids (VISUAL II)","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"R15-20260527","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"R16-20260527","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"R17-20260527","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE trial of adalimumab in juvenile idiopathic arthritis\u2013associated uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R18-20260527","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary outcomes of the STOP-Uveitis study","volume":"183","author":"Sepah","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R19-20260527","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Sarilumab for posterior segment noninfectious uveitis (SATURN)","volume":"126","author":"Heissigerov\u00e1","year":"2019","journal-title":"Ophthalmology"},{"key":"R20-20260527","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"key":"R21-20260527","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R22-20260527","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","article-title":"Intravitreal infliximab in refractory uveitis in Behcet\u2019s disease: A safety and efficacy clinical study","volume":"36","author":"Hamza","year":"2016","journal-title":"Retina"},{"key":"R23-20260527","first-page":"567","article-title":"Multiple sclerosis following anti-tumor necrosis factor-alpha therapy for psoriasis","volume":"153","author":"Napolitano","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"key":"R24-20260527","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20260527","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s10067-016-3527-z","article-title":"The emerging role of interleukin-1 in eye diseases","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R26-20260527","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin-1 inhibition in Beh\u00e7et\u2019s disease\u2013related uveitis","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R27-20260527","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-019-0182-y","article-title":"Interleukin-6 inhibition in non-infectious uveitis","volume":"9","author":"Karkhur","year":"2019","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R28-20260527","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in noninfectious uveitis","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"R29-20260527","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","article-title":"Ustekinumab for non-infectious uveitis in Crohn\u2019s disease","volume":"14","author":"Chateau","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R30-20260527","first-page":"67","article-title":"Systemic biologic agents in noninfectious uveitis","volume":"8","author":"Pasadhika","year":"2014","journal-title":"Biologics"},{"key":"R31-20260527","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/IAE.0000000000001563","article-title":"Long-term rituximab therapy in refractory posterior uveitis","volume":"38","author":"Lasave","year":"2018","journal-title":"Retina"},{"key":"R32-20260527","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s10067-014-2781-1","article-title":"Rituximab in Vogt\u2013Koyanagi\u2013Harada disease","volume":"34","author":"Caso","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R33-20260527","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Rituximab in ANCA-positive vasculitis","volume":"257","author":"Eriksson","year":"2005","journal-title":"J Intern Med"},{"key":"R34-20260527","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12348-025-00522-5","article-title":"Safety and efficacy of rituximab in refractory noninfectious uveitis and scleritis","volume":"15","author":"Al Ghulaiga","year":"2025","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R35-20260527","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R36-20260527","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in renal ANCA vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"R37-20260527","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/bjo-2022-321585","article-title":"Abatacept for active birdshot uveitis","volume":"108","author":"Schauwvlieghe","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"R38-20260527","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept in refractory JIA-related uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res"},{"key":"R39-20260527","doi-asserted-by":"crossref","first-page":"e0154564","DOI":"10.1371\/journal.pone.0154564","article-title":"mTOR inhibition in DSS-induced colitis","volume":"11","author":"Hu","year":"2016","journal-title":"PLoS One"},{"key":"R40-20260527","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Sirolimus for noninfectious uveitis: SAVE study","volume":"3","author":"Nguyen","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R41-20260527","first-page":"T3","article-title":"Intravitreal sirolimus dosing in noninfectious uveitis","volume":"114","author":"Nguyen","year":"2016","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R42-20260527","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Intravitreal sirolimus in noninfectious uveitis (SAKURA)","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"key":"R43-20260527","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R44-20260527","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R45-20260527","article-title":"JAK inhibitors in Blau syndrome","volume":"14","author":"\u00c1lvarez-Reguera","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R46-20260527","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000336324","article-title":"Interferon-\u03b1 therapy in noninfectious uveitis","volume":"51","author":"Deuter","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"R47-20260527","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/09273948.2018.1431292","article-title":"Interferon alpha-2a in postinfectious uveitis","volume":"27","author":"Invernizzi","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R48-20260527","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/09273948.2019.1604001","article-title":"Efficacy and Safety of Interferon Alpha 2A and Pegylated Interferon Alpha 2A in Inflammatory Macular Edema","volume":"28","author":"Couret","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"R49-20260527","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","article-title":"Interferon for MS-associated uveitis","volume":"89","author":"Becker","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R50-20260527","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/09273940601025966","article-title":"Efficacy of intravenous immunoglobulin treatment in refractory uveitis","volume":"14","author":"Onal","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"R51-20260527","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bjo.85.11.1287","article-title":"Intravenous immunoglobulin for ocular Beh\u00e7et\u2019s disease","volume":"85","author":"Seider","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R52-20260527","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1076\/ocii.10.4.239.15589","article-title":"Medical treatment of cystoid macular edema","volume":"10","author":"Rothova","year":"2002","journal-title":"Ocul Immunol Inflamm"},{"key":"R53-20260527","first-page":"11206721211024809","article-title":"Topical interferon in inflammatory macular edema","volume":"31","author":"Kawali","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"R54-20260527","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1093\/rheumatology\/keac552","article-title":"BSR guideline on drugs in pregnancy and breastfeeding","volume":"62","author":"Schreiber","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R55-20260527","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4103\/ijo.IJO_998_20","article-title":"Tofacitinib in Vogt-Koyanagi-Harada disease","volume":"68","author":"Dutta Majumder","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R56-20260527","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/09273948.2024.2323671","article-title":"Tofacitinib for refractory uveitis and scleritis in children: A case series","volume":"32","author":"Dutta Majumder","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R57-20260527","first-page":"25158414211027707","article-title":"Pediatric uveitis: A retrospective analysis at a tertiary eye care hospital in South India","volume":"13","author":"Raveendra Murthy","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"R58-20260527","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/09273948.2022.2113805","article-title":"Tofacitinib in scleritis: A case series","volume":"32","author":"Pyare","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R59-20260527","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4103\/ijo.IJO_789_22","article-title":"Tofacitinib in juvenile idiopathic arthritis-associated uveitis","volume":"2","author":"Babu","year":"2022","journal-title":"Indian J Ophthalmol Case Rep"},{"key":"R60-20260527","doi-asserted-by":"crossref","first-page":"367","DOI":"10.31138\/mjr.20230828.ti","article-title":"Tofacitinib in refractory scleritis: A case series","volume":"34","author":"Dey","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"R61-20260527","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.4103\/ijo.IJO_1519_20","article-title":"Commentary: Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India","volume":"68","author":"Tyagi","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R62-20260527","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/IJO.IJO_1126_24","article-title":"Biologics in ocular inflammatory diseases-Experience from a tertiary referral eye care center in South India","volume":"73","author":"Babu","year":"2025","journal-title":"Indian J Ophthalmol"},{"key":"R63-20260527","doi-asserted-by":"crossref","first-page":"S584","DOI":"10.4103\/IJO.IJO_3131_22","article-title":"Clinical profile and treatment outcomes in pediatric uveitis-A series from South India","volume":"72","author":"Mooss","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R64-20260527","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/IJO.IJO_2964_24","article-title":"Failure of primary immunosuppressive agents in uveitis","volume":"73","author":"Kawali","year":"2025","journal-title":"Indian J Ophthalmol"},{"key":"R65-20260527","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/ijo.IJO_1411_22","article-title":"Clinical profile and management of granulomatosis with polyangiitis-associated scleritis from a tertiary care hospital in South India","volume":"71","author":"Mohanan-Earatt","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R66-20260527","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4103\/IJO.IJO_61_25","article-title":"JAK-STAT inhibitors in noninfectious uveitis-A review","volume":"73","author":"Pyare","year":"2025","journal-title":"Indian J Ophthalmol"},{"key":"R67-20260527","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/jop.2021.0098","article-title":"Current knowledge of biologics in treatment of noninfectious uveitis","volume":"38","author":"Gupta","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"R68-20260527","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7812\/TPP\/17-041","article-title":"Management of uveitis in spondyloarthropathy: Current trends","volume":"22","author":"Gupta","year":"2018","journal-title":"Perm J"},{"key":"R69-20260527","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1007\/s10792-020-01496-0","article-title":"Recent advances in the management of non-infectious posterior uveitis","volume":"40","author":"Singh","year":"2020","journal-title":"Int Ophthalmol"},{"key":"R70-20260527","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.preteyeres.2025.101380","article-title":"Immunomodulatory therapy in non-infectious uveitis: Current landscape, gaps, and future directions","volume":"108","author":"Agrawal","year":"2025","journal-title":"Prog Retin Eye Res"},{"key":"R71-20260527","first-page":"25158414221097418","article-title":"A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology","volume":"14","author":"Hasan","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"key":"R72-20260527","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4103\/ijo.IJO_966_20","article-title":"Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India","volume":"68","author":"Sadhu","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R73-20260527","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4103\/ijo.IJO_629_18","article-title":"Uveitis in sporadic Blau syndrome: Long-term follow-up of a refractory case treated successfully with adalimumab","volume":"66","author":"Naik","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R74-20260527","doi-asserted-by":"crossref","first-page":"103401","DOI":"10.1016\/j.jaut.2025.103401","article-title":"Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis","volume":"153","author":"Maccora","year":"2025","journal-title":"J Autoimmun"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3239_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:56Z","timestamp":1787067836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3239_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3239_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2025-12-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}